Genentech says drug improves vision after 1 year
Key points
- Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections.
- The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal.
- Genentech has said that U.S. regulators would likely require its drug to show a difference - in favor of Lucentis - of 15 letters.
- Each line on a reading chart consists of five letters, so a 15-letter difference is equivalent to the difference in reading three lines of a reading chart.
Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections.
The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal.
Genentech has said that U.S. regulators would likely require its drug to show a difference - in favor of Lucentis - of 15 letters. Each line on a reading chart consists of five letters, so a 15-letter difference is equivalent to the difference in reading three lines of a reading chart.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
